StemBioSys acquires a majority stake in Cartox

Acquisitions

▤ Summary

StemBioSys has acquired a majority stake in Cartox and plans to buy the rest once certain milestones are met. Cartox develops technology for pre-clinical cardiac safety testing and cardiotoxicity screening of new drugs. The combined companies will pair Cartox’s imaging and cardiomyocyte expertise with StemBioSys’s matrix technology to build a broader drug screening solution. The deal also strengthens their commercialization plan and supports ongoing grant-funded product development through early 2021.

▥ Classifications

industries
No industries detected
applications
No applications detected

◇ AskAI Classifications

Labels
No AI classifications detected

▦ Linked Companies